A recent drug-industry funded study in Health Affairs Scholar found that increased utilization, rather than rising drug prices, drives 340B program growth.
Amgen announced it will exempt Tennessee from its contract pharmacy restrictions, surprising some providers in the state due a grandfather clause in Tennessee's law.
U.S. Rep. Victoria Spartz (R-Ind.) introduced the legislation (H.R. 3222), known as the “Stopping Medicare Abuses to Restore Trust in Health Care Act” or SMART Health Care Act, on May 6. 340B provider advocates strongly oppose the bill's 340B provisions.
Key briefs and motions were filed recently in the 8th Circuit and 5th Circuit Appeals Courts, as well as federal district courts in Utah and South Dakota.
